The Food and Drug Administration is imposing a clinical hold on several of Seattle Genetics’ early-stage studies involving an experimental cancer drug following the deaths of four people, Reuters ...

An acquisition last year by a Pacific Northwest biotech company has paid off, in the form of a successful registration-directed breast cancer study. The company – which is based in the suburb of ...

-Collaboration Combines Seattle Genetics’ Expertise in Cancer Targets and Antibody-Based Therapies with Unum’s Novel Antibody-Coupled T-cell Receptor (ACTR) Technology- -Companies to Focus on the ...

LOS ANGELES, Sept 24 (Reuters) - Biotechnology company Seattle Genetics will announce on Monday results from a pivotal trial of experimental drug brentuximab vedotin in patients with Hodgkin lymphoma.

Seattle Genetics and Bayer HealthCare will collaborate on developing new antibody-drug conjugates (ADCs). Bayer is paying up-front and option exercise fees of up to $20 million for rights to use ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS ...

Clay Siegall is the founder and CEO of Seattle Genetics. Anthony Bolante | PSBJ To continue reading this content, please enable JavaScript in your browser settings ...

Fintel reports that Capital International Investors has filed a 13G/A form with the SEC disclosing ownership of 18.06MM shares of Seattle Genetics, Inc. (SGEN). This represents 9.7% of the company. In ...

Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago. These figures are ...

The field of human genetics and genomics research has seen spectacular progress and advances in human health and well-being that are nothing short of remarkable. In just a few years, we have been able ...